<html xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">

<title>Opportunities for Basic and Clinical Research</title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Cathy Russin</o:Author>
  <o:LastAuthor>Carol Haggans</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>3</o:TotalTime>
  <o:LastPrinted>2002-08-28T18:17:00Z</o:LastPrinted>
  <o:Created>2002-11-04T19:33:00Z</o:Created>
  <o:LastSaved>2002-11-04T19:33:00Z</o:LastSaved>
  <o:Pages>3</o:Pages>
  <o:Words>1788</o:Words>
  <o:Characters>10197</o:Characters>
  <o:Company>roswell park cancer</o:Company>
  <o:Lines>84</o:Lines>
  <o:Paragraphs>20</o:Paragraphs>
  <o:CharactersWithSpaces>12522</o:CharactersWithSpaces>
  <o:Version>9.4402</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackRevisions/>
  <w:DrawingGridHorizontalSpacing>4.5 pt</w:DrawingGridHorizontalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>2</w:DisplayHorizontalDrawingGridEvery>
  <w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery>
  <w:Compatibility>
   <w:FootnoteLayoutLikeWW8/>
   <w:ShapeLayoutLikeWW8/>
   <w:AlignTablesRowByRow/>
   <w:ForgetLastTabAlignment/>
   <w:LayoutRawTableWidth/>
   <w:LayoutTableRowsApart/>
  </w:Compatibility>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	tab-stops:27.0pt .5in;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:8.5in 11.0in;
	margin:.9in 1.0in .9in 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:.5in'>

<div class=Section1>

<p class=MsoTitle><span style='font-size:14.0pt;mso-bidi-font-size:12.0pt'>Opportunities
for Basic and Clinical Research<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'><span style='font-size:14.0pt;mso-bidi-font-size:12.0pt'>on Conjugated
Linoleic Acid<o:p></o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></b></p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'>Submitted by<o:p></o:p></b></p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'>Clement Ip, Ph.D.<o:p></o:p></b></p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'>Dept. of Cancer Prevention<o:p></o:p></b></p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'>Roswell Park Cancer Institute<o:p></o:p></b></p>

<p class=MsoNormal align=center style='text-align:center'><b style='mso-bidi-font-weight:
normal'>Buffalo, NY<span style="mso-spacerun: yes">  </span>14263<o:p></o:p></b></p>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>A
conference, entitled “Perspectives on Conjugated Linoleic Acid Research:
Current Status and Future Directions,” was held at the National Institutes of
Health in May 15-16, 2002.<span style="mso-spacerun: yes">  </span>The program
content, abstracts, and some of the presentations can be found at <a
href="http://ods.od.nih.gov/News/CLA_Conference.aspx">http://ods.od.nih.gov/News/CLA_Conference.aspx</a>.
Conjugated linoleic acid (abbreviated to CLA) is a term which refers to a
family of 18-carbon fatty acid isomers with two conjugated double bonds.<span
style="mso-spacerun: yes">  </span>Different CLA isomers have been identified
based on the position as well as the arrangement of the double bonds.<span
style="mso-spacerun: yes">  </span>Along the acyl chain, the two conjugated
double bonds could<span style="mso-spacerun: yes">  </span>be in positions 7
and 9, 8 and 10, 9 and 11, 10 and 12, or 11 and 13.<span style="mso-spacerun:
yes">  </span>These are known as positional isomers.<span style="mso-spacerun:
yes">  </span>Additionally, there could be four possible spatial orientations
to the two double bonds as denoted by the nomenclature of <i style='mso-bidi-font-style:
normal'>cis,cis</i> (<i style='mso-bidi-font-style:normal'>c,c</i>); <i
style='mso-bidi-font-style:normal'>cis,trans</i> (<i style='mso-bidi-font-style:
normal'>c,t</i>); <i style='mso-bidi-font-style:normal'>trans,cis</i> (<i
style='mso-bidi-font-style:normal'>t,c</i>) and <i style='mso-bidi-font-style:
normal'>trans,trans </i>(<i style='mso-bidi-font-style:normal'>t,t</i>). These
are known as geometric isomers.<span style="mso-spacerun: yes"> 
</span>Sophisticated analytical techniques have only recently been developed to
separate the spectrum of CLA isomers.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText style='margin-top:3.0pt'><span style='mso-tab-count:1'>         </span>Dairy
products are rich sources of CLA, in particular the <i style='mso-bidi-font-style:
normal'>c</i>9,<i style='mso-bidi-font-style:normal'>t</i>11-CLA isomer. The
microbial biohydrogenation of linoleic acid to stearic acid involves the
formation of <i style='mso-bidi-font-style:normal'>c</i>9,<i style='mso-bidi-font-style:
normal'>t</i>11-CLA as the first step, catalyzed by an isomerase-mediated
reaction unique to bacteria in the rumen of dairy cows.<span
style="mso-spacerun: yes">  </span>A portion of CLA in milk fat arises from CLA
that has escaped complete rumen biohydrogenation. A more significant portion of
CLA in dairy cows is synthesized in the tissues by <span style='font-family:
Symbol;mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-char-type:symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type:
symbol;mso-symbol-font-family:Symbol'>D</span></span>9-desaturase from vaccenic
acid (<i style='mso-bidi-font-style:normal'>t</i>11-18:1), another intermediate
in the rumen biohydrogenation pathway<!--[if supportFields]><span
style='mso-element:field-begin'></span> QUOTE &quot;&quot; <span
style='display:none;mso-hide:all'><span style='mso-element:field-begin'></span><span
style="mso-spacerun: yes"> </span>ADDIN REFMAN
ÿ\11\05‘\19\01\00\00\00\00\01\00\00(C:\5CProgram Files\5CReference Manager
9\5CCIP\03\00\03511#Corl, Baumgard, et al. 2001 511 /id\00#\00 <span
style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->. Over 90% of CLA in food is
the <i style='mso-bidi-font-style:normal'>c</i>9,<i style='mso-bidi-font-style:
normal'>t</i>11-CLA isomer.<span style="mso-spacerun: yes">  </span>CLA can
also be made synthetically from linoleic acid by the process of heat alkaline
isomerization. Such a synthetic preparation contains a mixture of CLA
isomers.<span style="mso-spacerun: yes">  </span>The two major ones are <i
style='mso-bidi-font-style:normal'>c</i>9,<i style='mso-bidi-font-style:normal'>t</i>11-CLA
and <i style='mso-bidi-font-style:normal'>t</i>10,<i style='mso-bidi-font-style:
normal'>c</i>12-CLA; they constitute about 80% of the total in approximately
1:1 ratio. The remaining isomers are <i style='mso-bidi-font-style:normal'>c</i>7,<i
style='mso-bidi-font-style:normal'>t</i>9-CLA, <i style='mso-bidi-font-style:
normal'>t</i>8,<i style='mso-bidi-font-style:normal'>c</i>10-CLA and <i
style='mso-bidi-font-style:normal'>c</i>11,<i style='mso-bidi-font-style:normal'>t</i>13-CLA.<span
style="mso-spacerun: yes">  </span>Most of the studies on CLA have used the
synthetic mixed isomer preparation which is available commercially from a
number of lipid specialty vendors.<span style="mso-spacerun: yes">  </span>In
the last few years, biological research with individual CLA isomers has focused
exclusively on <i style='mso-bidi-font-style:normal'>c</i>9,<i
style='mso-bidi-font-style:normal'>t</i>11-CLA and <i style='mso-bidi-font-style:
normal'>t</i>10,<i style='mso-bidi-font-style:normal'>c</i>12-CLA. The reason
for this is that highly purified preparations of these two CLA isomers have
been successfully produced by various methodologies, while the other isomers
have yet to be acquired in sufficient quantities. In order to simplify the
complicated terminologies, <i style='mso-bidi-font-style:normal'>c</i>9,<i
style='mso-bidi-font-style:normal'>t</i>11-CLA is abbreviated to 9,11-CLA, and <i
style='mso-bidi-font-style:normal'>t</i>10,<i style='mso-bidi-font-style:normal'>c</i>12-CLA
to 10,12-CLA.</p>

<p class=MsoBodyText style='margin-top:3.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText style='margin-top:3.0pt'><span style='mso-tab-count:1'>         </span>Numerous
physiological properties have been attributed to CLA. Health benefits include
the action of CLA as an anti-carcinogenic<!--[if supportFields]><span
style='mso-element:field-begin'></span> QUOTE &quot;&quot; <span
style='display:none;mso-hide:all'><span style='mso-element:field-begin'></span><span
style="mso-spacerun: yes"> </span>ADDIN REFMAN
ÿ\11\05‘\19\01\00\00\00\00\01\00\00(C:\5CProgram Files\5CReference Manager 9\5CCIP\03\00\0226\1DIp,
Jiang, et al. 1997 26 /id\00\1D\00 <span style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>QUOTE &quot;&quot; <span style='display:none;mso-hide:all'><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>ADDIN REFMAN ÿ\11\05‘\19\01\00\00\00\00\01\00\00(C:\5CProgram
Files\5CReference Manager 9\5CCIP\03\00\03171\19Ip &amp; Scimeca 1997 171
/id\00\19\00 <span style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>QUOTE &quot;&quot; <span style='display:none;mso-hide:all'><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>ADDIN REFMAN ÿ\11\05‘\19\01\00\00\00\00\01\00\00(C:\5CProgram
Files\5CReference Manager 9\5CCIP\03\00\0218!Thompson, Zhu, et al. 1997 18
/id\00!\00 <span style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>QUOTE &quot;&quot; <span style='display:none;mso-hide:all'><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>ADDIN REFMAN ÿ\11\05‘\19\01\00\00\00\00\01\00\00(C:\5CProgram
Files\5CReference Manager 9\5CCIP\03\00\0216 Belury, Bird, et al. 1996 16
/id\00 \00 <span style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>QUOTE &quot;&quot; <span style='display:none;mso-hide:all'><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>ADDIN REFMAN ÿ\11\05‘\19\01\00\00\00\00\01\00\00(C:\5CProgram
Files\5CReference Manager 9\5CCIP\03\00\03170&amp;Visonneau, Cesano, et al.
1997 170 /id\00&amp;\00 <span style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>QUOTE &quot;&quot; <span style='display:none;mso-hide:all'><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>ADDIN REFMAN ÿ\11\05‘\19\01\00\00\00\00\01\00\00(C:\5CProgram
Files\5CReference Manager 9\5CCIP\03\00\03226&amp;Cesano, Visonneau, et al.
1998 226 /id\00&amp;\00 <span style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>QUOTE &quot;&quot; <span style='display:none;mso-hide:all'><span
style='mso-element:field-begin'></span><span style="mso-spacerun:
yes"> </span>ADDIN REFMAN ÿ\11\05‘\19\01\00\00\00\00\01\00\00(C:\5CProgram
Files\5CReference Manager 9\5CCIP\03\00\03512!Hubbard, Lim, et al. 2000 512
/id\00!\00 <span style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->, anti-atherosclerotic<!--[if supportFields]><span
style='mso-element:field-begin'></span> QUOTE &quot;&quot; <span
style='display:none;mso-hide:all'><span style='mso-element:field-begin'></span><span
style="mso-spacerun: yes"> </span>ADDIN REFMAN
ÿ\11\05‘\19\01\00\00\00\00\01\00\00(C:\5CProgram Files\5CReference Manager
9\5CCIP\03\00\03470%Wilson, Nicolosi, et al. 2000 470 /id\00%\00 <span
style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->, anti-lipogenic and
anti-diabetogenic agent. Furthermore, CLA is known to modulate lipid metabolism
and immune function.<span style="mso-spacerun: yes">  </span>A major focus of
the conference was to review the literature on these topics.<span
style="mso-spacerun: yes">  </span>Once purified 9,11-CLA and 10,12-CLA became
available, there was increasing awareness that specific CLA isomers may be
responsible for certain biological or biochemical changes.<span
style="mso-spacerun: yes">  </span>CLA in the form of dietary supplements is
available from health food stores in North America and Europe.<span
style="mso-spacerun: yes">  </span>Although some of these formulations are of
dubious quality, for the most part they contain about 60% total of 9,11-CLA and
10,12-CLA as the major ingredients.<span style="mso-spacerun: yes"> 
</span>Because of easy public access to CLA and the relative lack of oversight
of label claims for dietary supplements, NIH is taking a closer look at the
current status of CLA research.</p>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>The
purpose of this report is not to recapitulate individual presentations.<span
style="mso-spacerun: yes">  </span>Instead, it is to identify research needs
that will be helpful in advancing our knowledge of CLA nutrition and biology.<span
style="mso-spacerun: yes">  </span>From a human nutrition standpoint, the current
food CLA database is inadequate to allow an assessment of CLA intake in a
meaningful way.<span style="mso-spacerun: yes">  </span>Since 9,11-CLA can be
synthesized endogenously from vaccenic acid which is present in dairy products,
the role of this biochemical reaction in contributing to tissue CLA
accumulation needs to be evaluated systematically.<span style="mso-spacerun:
yes">  </span>An equally important issue is the development of biomarkers of
chronic CLA intake.<span style="mso-spacerun: yes">  </span>The above
information is essential if we are to address the question of whether dietary
sources alone (i.e. not as a supplement) are sufficient to realize the
biological benefits of CLA.</p>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>CLA
has been reported to cause body fat reduction in growing animals (rodents and
pigs), and to depress milk fat synthesis in lactating cows and women.<span
style="mso-spacerun: yes">  </span>This effect appears to be unique to the
10,12-CLA isomer.<span style="mso-spacerun: yes">  </span>In human studies
which have used a mixture of 9,11-CLA and 10,12-CLA, the response of body fat
reduction is much less consistent.<span style="mso-spacerun: yes">  </span>The
questions that remain unanswered are related to:<span style="mso-spacerun:
yes">  </span>(a) whether the impact of CLA on lipid metabolism is different in
a growing animal versus a mature adult animal; (b) whether 9,11-CLA is able to
modulate the effect of 10,12-CLA on lipid metabolism in certain cases; (c)
whether the action of 10,12-CLA is primarily due to a suppression of de novo
lipid synthesis or an increase of lipolysis; and (d) whether the contribution
of these biochemical pathways may shift under various physiological conditions.</p>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Although
a number of epidemiological studies have examined the relationship between dairy
product consumption and cancer risk, there are only two case-control studies
which were designed specifically to investigate dietary/tissue CLA and cancer
morbidity in humans.<span style="mso-spacerun: yes">  </span>Both of these were
targeted to breast cancer.<span style="mso-spacerun: yes">  </span>Since these
were dietary studies, the reference CLA is the 9,11-CLA isomer.<span
style="mso-spacerun: yes">  </span>The study from Finland reported that in
postmenopausal women, dietary CLA and serum CLA were significantly lower in
cases than in controls.<span style="mso-spacerun: yes">  </span>The odds ratio,
after adjustment for known risk factors of breast cancer, was 0.4 in the
highest quintile versus the lowest,<span style="mso-spacerun: yes"> 
</span>suggesting that CLA may have a protective effect against breast
cancer.<span style="mso-spacerun: yes">  </span>The second study was based in
France, and breast fat CLA was used as an indicator of exposure.<span
style="mso-spacerun: yes">  </span>No protective effect of CLA on breast cancer
risk was found.<span style="mso-spacerun: yes">  </span>In view of the paucity
of epidemiological studies on CLA and cancer, additional information in this
area would be desirable.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>CLA
exerts a powerful anticancer effect in the rat mammary gland.<span
style="mso-spacerun: yes">  </span>There could be a number of underlying
reasons to explain why CLA is particularly effective in mammary cancer
prevention, at least in the animal model.<span style="mso-spacerun: yes"> 
</span>The mammary epithelium is embedded in an adipocyte-rich stroma, and
importantly, CLA is incorporated preferentially into adipocyte neutral
lipid.<span style="mso-spacerun: yes">  </span>CLA released from mammary
adipocytes may serve as a paracrine factor to block the clonal expansion of
premalignant epithelial cells and the differentiation of stromal-vascular stem
cells to endothelial cells.<span style="mso-spacerun: yes">  </span>Inhibition
of angiogenesis may represent a novel mechanism in the anti-cancer effect of
CLA.<span style="mso-spacerun: yes">  </span>This could be a potentially
fruitful area of research in the future.</p>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify;text-indent:.5in'>Although CLA has
been shown to protect against tumorigenesis in other animal models, the
database is far less extensive, and in most cases, the experiments have not
been replicated sufficiently to reach consensus.<span style="mso-spacerun:
yes">  </span>Furthermore, there is a vacuum of knowledge regarding the
activity of CLA isomers in animal carcinogenesis models.<span
style="mso-spacerun: yes">  </span>Cell culture studies have been used to
investigate the effect of CLA on proliferation and apoptosis.<span
style="mso-spacerun: yes">  </span>However, the physiological relevance of
these in vitro findings is questionable since many of these experiments were
done with very high levels of CLA dissolved in an organic solvent.<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-align:justify;text-indent:.5in'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify;text-indent:.5in'>The anti-diabetogenic
effect of CLA is interesting but is very poorly defined; there is little
information in the literature on this subject.<span style="mso-spacerun: yes"> 
</span>The presence of confounding factors associated with the experimental
model, the Zucker diabetic fatty rat further contributes to our lack of a clear
understanding of the ability of CLA to lower blood glucose.<span
style="mso-spacerun: yes">  </span>These factors include rodent strain
differences, the response of pre-diabetic versus diabetic conditions, insulin
resistance effect, reduced body fat mass, changing blood lipid profile, as well
as the duration and dose of CLA treatment.<span style="mso-spacerun: yes"> 
</span>These issues need to be resolved before undertaking any controlled
intervention trials in humans.</p>

<p class=MsoNormal style='text-align:justify;text-indent:.5in'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal>Research on the biology of CLA must be accompanied by equal
attention to two fundamental aspects of CLA biochemistry.<span
style="mso-spacerun: yes">  </span>It has been well documented that CLA is
metabolized to downstream elongation and desaturation products following the
pathway of linoleic acid metabolism.<span style="mso-spacerun: yes"> 
</span>The identification of conjugated arachidonic acid in particular has
engendered a great deal of interest because of the potential that it may: (a)
deplete the availability of arachidonic acid; (b) interfere with
cyclooxygenase- or lipoxygenase-mediated biosynthesis of eicosanoids from
arachidonic acid; or (c) produce its own eicosanoid analogs which may have
unique biological activities.<span style="mso-spacerun: yes">  </span>Thus the
role of CLA metabolism in contributing to the effect of CLA should be an area
of future research emphasis.<span style="mso-spacerun: yes">  </span>A second
area that is begging for attention is related to the intracellular signaling
mechanism of CLA or CLA metabolites.<span style="mso-spacerun: yes"> 
</span>CLA has been shown to be a high affinity ligand and activator of
peroxisome proliferator-activated receptors (PPAR), a family of transcription
factors known to affect gene expression in a tissue-specific manner.<span
style="mso-spacerun: yes">  </span>Isoforms of PPAR are widely distributed,
although in highly variable amounts, in different tissues.<span
style="mso-spacerun: yes">  </span>Comprehensive studies are needed to
elucidate the significance of individual PPAR family members in mediating the
effects of CLA in a given organ.<span style="mso-spacerun: yes">  </span>In this
regard, the use of cutting-edge genomics technology would be a valuable tool to
characterize signaling pathways and molecular targets that are relevant to the
action of CLA under defined conditions.<span style="mso-spacerun: yes"> 
</span>Other candidates for mediating the transcriptional effects of CLA may
include the sterol-regulatory binding protein (SREBP) family, the activity or
expression of which has been shown to be altered by polyunsaturated fatty
acids, but for which the effects of CLA have not yet been investigated.<span
style="mso-spacerun: yes">  </span>Finally, the many biological activities
attributed to individual CLA isomers suggest that there is a high degree of
tissue specificity with respect to the mechanism by which CLA and/or its
metabolites exert their effects.<span style="mso-spacerun: yes">  </span>Unraveling
this complexity at the cellular and molecular levels will be the challenge of
the CLA field in the years to come.</p>

</div>

</body>

</html>
